ArticleGynecologic oncology reports2025
Prognostic value of CT-PCI and CA-125 changes following neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A retrospective study from Vietnam.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to evaluate the prognostic significance of CT-based Peritoneal Cancer Index (CT-PCI) scores and serum CA-125 levels, assessed before and after neoadjuvant chemotherapy (NACT), in relation to surgical outcomes and survival among patients with advanced-stage epithelial ovarian cancer (EOC). Methods: This retrospective study included 96 patients with advanced EOC who received NACT followed by interval debulking surgery (IDS) at Hanoi Medical University Hospital and the National Cancer Hospital (K Hospital), Vietnam, between 2019 and 2024. CT-PCI scores and CA-125 levels were assessed both pre- and post-NACT. The associations between these changes and surgical outcomes, particularly optimal cytoreduction, were analyzed. Results: The mean age was 59.17 years (SD = 9.78), with 94.8 % of patients diagnosed with high-grade serous carcinoma and 51.0 % classified as FIGO stage IIIC. Median CT-PCI scores decreased from 14.0 (IQR: 7.0-19.0) to 4.0 (IQR: 2.0-8.0), and median CA-125 levels declined from 1248 U/ml (IQR: 389-2855) to 31.25 U/ml (IQR: 16.75-147.3) post-treatment (both p < 0.01). Optimal cytoreduction was achieved in 84.4 % of cases. Post-NACT CT-PCI scores and CA-125 levels > 35 U/ml were significantly associated with suboptimal cytoreduction (cOR = 1.15, 95 % CI: 1.03-1.27, p = 0.01; and cOR = 5.26, 95 % CI: 1.38-33.00, p = 0.02, respectively). Median progression-free survival was 20.5 months; median overall survival was 36.7 months. Conclusion: Post-treatment CT-PCI scores and CA-125 levels are valuable prognostic indicators in advanced epithelial ovarian cancer. Their reduction following NACT correlates significantly with improved progression-free and overall survival. These findings support their potential role in informing clinical decision-making and tailoring personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.